Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
Adaptive Biotechnologies (Nasdaq: ADPT) has announced its participation in two upcoming investor conferences. The company, which specializes in translating adaptive immune system genetics into clinical products, will attend the BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT on February 12, 2025, and the TD Cowen 45th Annual Health Care Conference in Boston, MA on March 3, 2025.
At the TD Cowen conference, the company will participate in a fireside chat scheduled for 11:10 a.m. Eastern Time. Investors and interested parties can access live and archived webcasts of the sessions through the 'Investors' section of Adaptive Biotechnologies' website at www.adaptivebiotech.com.
Adaptive Biotechnologies (Nasdaq: ADPT) ha annunciato la sua partecipazione a due prossime conferenze per investitori. L'azienda, specializzata nella traduzione della genetica del sistema immunitario adattivo in prodotti clinici, parteciperà alla 12ª Conferenza Annuale BTIG su MedTech, Salute Digitale, Scienze della Vita e Strumenti Diagnostici a Snowbird, UT, il 12 febbraio 2025, e alla 45ª Conferenza Annuale TD Cowen sulla Sanità a Boston, MA, il 3 marzo 2025.
Durante la conferenza TD Cowen, l'azienda prenderà parte a un colloquio intimo programmato per le 11:10 ora orientale. Gli investitori e i soggetti interessati possono accedere alle dirette e alle registrazioni delle sessioni attraverso la sezione 'Investitori' del sito web di Adaptive Biotechnologies all'indirizzo www.adaptivebiotech.com.
Adaptive Biotechnologies (Nasdaq: ADPT) ha anunciado su participación en dos próximas conferencias para inversores. La empresa, que se especializa en traducir la genética del sistema inmunitario adaptativo en productos clínicos, asistirá a la 12ª Conferencia Anual de BTIG sobre MedTech, Salud Digital, Ciencias de la Vida y Herramientas Diagnósticas en Snowbird, UT, el 12 de febrero de 2025, y a la 45ª Conferencia Anual de TD Cowen sobre Atención Médica en Boston, MA, el 3 de marzo de 2025.
En la conferencia de TD Cowen, la empresa participará en una charla junto a la chimenea programada para las 11:10 a.m. hora del Este. Los inversores y partes interesadas pueden acceder a las transmisiones en vivo y grabadas de las sesiones a través de la sección 'Inversores' del sitio web de Adaptive Biotechnologies en www.adaptivebiotech.com.
Adaptive Biotechnologies (Nasdaq: ADPT)는 다가오는 두 개의 투자자 회의에 참여한다고 발표했습니다. 적응 면역 시스템 유전자를 임상 제품으로 변환하는 데 전문화된 이 회사는 2025년 2월 12일 유타주 스노우버드에서 열리는 BTIG 제12회 연례 MedTech, 디지털 헬스, 생명 과학 및 진단 도구 회의와 2025년 3월 3일 매사추세츠주 보스턴에서 열리는 TD Cowen 제45회 연례 건강 관리 회의에 참석할 예정입니다.
TD Cowen 회의에서 이 회사는 동부 표준시 오전 11:10에 예정된 파이어사이드 채팅에 참여할 것입니다. 투자자와 관심 있는 당사자는 Adaptive Biotechnologies 웹사이트 www.adaptivebiotech.com의 '투자자' 섹션을 통해 세션의 실시간 방송 및 녹화된 내용을 이용할 수 있습니다.
Adaptive Biotechnologies (Nasdaq: ADPT) a annoncé sa participation à deux prochaines conférences pour investisseurs. L'entreprise, spécialisée dans la traduction de la génétique du système immunitaire adaptatif en produits cliniques, participera à la 12e conférence annuelle BTIG sur les MedTech, la santé numérique, les sciences de la vie et les outils de diagnostic à Snowbird, UT le 12 février 2025, et à la 45e conférence annuelle TD Cowen sur les soins de santé à Boston, MA le 3 mars 2025.
Lors de la conférence TD Cowen, l'entreprise participera à une discussion informelle prévue à 11h10, heure de l'Est. Les investisseurs et les parties intéressées peuvent accéder aux webdiffusions en direct et aux rediffusions des sessions via la section 'Investisseurs' du site Web d'Adaptive Biotechnologies à l'adresse www.adaptivebiotech.com.
Adaptive Biotechnologies (Nasdaq: ADPT) hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Das Unternehmen, das sich auf die Übersetzung der Genetik des adaptiven Immunsystems in klinische Produkte spezialisiert hat, wird an der 12. jährlichen BTIG-Konferenz über MedTech, digitale Gesundheit, Lebenswissenschaften und Diagnosetools in Snowbird, UT, am 12. Februar 2025, und an der 45. jährlichen TD Cowen Gesundheitskonferenz in Boston, MA, am 3. März 2025, teilnehmen.
Auf der TD Cowen-Konferenz wird das Unternehmen an einem geplanten Fireside-Chat um 11:10 Uhr Eastern Time teilnehmen. Investoren und interessierte Parteien können über den Bereich 'Investoren' auf der Website von Adaptive Biotechnologies unter www.adaptivebiotech.com auf die Live- und aufgezeichneten Webcasts der Sitzungen zugreifen.
- None.
- None.
SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.
- BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT
Participating on Wednesday, February 12, 2025
- TD Cowen 45th Annual Health Care Conference in Boston, MA
Fireside chat on Monday, March 3, 2025, at 11:10 a.m. Eastern Time
Interested parties may access live and archived webcasts of the session on the “Investors” section of the company website at: www.adaptivebiotech.com.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com
FAQ
When is Adaptive Biotechnologies (ADPT) presenting at the TD Cowen Healthcare Conference in 2025?
Which investor conferences will Adaptive Biotechnologies (ADPT) attend in early 2025?
How can investors access Adaptive Biotechnologies' (ADPT) conference presentations?
What type of presentation will ADPT give at the TD Cowen Healthcare Conference?
